Home » Stocks » VIRI

Virios Therapeutics, Inc. (VIRI)

Stock Price: $5.50 USD -0.08 (-1.43%)
Updated Apr 19, 2021 11:19 AM EDT - Market open
Market Cap 27.10M
Revenue (ttm) n/a
Net Income (ttm) -10.35M
Shares Out 4.93M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $5.50
Previous Close $5.58
Change ($) -0.08
Change (%) -1.43%
Day's Open 5.60
Day's Range 5.42 - 5.86
Day's Volume 10,473
52-Week Range 4.60 - 16.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

1 week ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

1 month ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

1 month ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

1 month ago - Business Wire

Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.

Other stocks mentioned: BRO, BSRR, CHMG, CYTH, FAST, SRGA
2 months ago - InvestorPlace

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal im...

2 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal im...

2 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (VIRI) will present at the H.C. Wainwright Virtual BioConnect Conference, taking place January 11-14, 2021.

3 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal im...

3 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (the “Company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal i...

4 months ago - Business Wire

About VIRI

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing an... [Read more...]

Industry
Biotechnology
IPO Date
Dec 17, 2020
CEO
Greg Duncan
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
VIRI
Full Company Profile

Financial Performance

Financial Statements